TorMagnus Pharmaceuticals
A drug discovery company combining computational methods and genetics to identify and validate therapeutic targets, initially focused on Parkinson’s disease. The organization applies machine learning to find converging disease pathways, performs laboratory validation of targets, and develops small-molecule modulators with a pipeline intended to scale to other neurodegenerative indications.
Industries
artificial-intelligence
biotechnology
simulation
Nr. of Employees
small (1-50)
TorMagnus Pharmaceuticals
San Francisco, California, United States, North America
Services
Computational identification of converging disease pathways and therapeutic targets using machine learning applied to genetic and biological data.
Laboratory validation of computationally identified targets and development of small-molecule modulators against prioritized targets.
Computational identification of converging disease pathways and therapeutic targets using machine learning applied to genetic and biological data.
Laboratory validation of computationally identified targets and development of small-molecule modulators against prioritized targets.
Expertise Areas
- Parkinson's disease-focused drug discovery
- AI-driven target discovery
- Genetics-based target identification
- Small-molecule medicinal chemistry
Key Technologies
- Machine learning
- Computational biology
- Genomic analysis
- Pathway convergence analysis